Atea Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:AVIR) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Cash from operating activities 23.04 M30.4 M30.56 M32.87 M40.38 M 134.21 M Cash from investing activities -122.01 M-3.37 M85.61 M15.29 M41.3 M 138.83 M Cash from financing activities 117 K0347 K14.09 M11.3 M 25.75 M Free cash flow 23.04 M30.4 M30.56 M32.87 M40.38 M 134.21 M

新闻

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea: Ergebnisse der Phase-3-Studie zur HCV-Behandlung für Mitte 2026 erwartet

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea completes enrollment in HCV treatment phase 3 trial

Atea Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2025-11-14

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Atea Pharmaceuticals verfehlt Gewinnprognose, Aktie steigt trotzdem

Cisco, Flutter, Manulife and more set to report earnings Wednesday

Ateas Hepatitis-C-Kombinationstherapie zeigt in Modellstudie vielversprechende Ergebnisse

Atea’s hepatitis C drug combination shows promising results in modeling study